Physician profile
Mark Hellreich
NPI 1396831830
$3,493.28
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $680 · 2020: $447 · 2021: $427 · 2022: $1,219 · 2023: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $701 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $701.25 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $832.74 | 2019-2023 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $545.58 | 2019-2023 | Ofev, Stiolto Respimat |
| Grifols USA, LLC | $457.08 | 2019-2023 | Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals Lp | $385.10 | 2019-2023 | Breztri, Tezspire |
| Regeneron Healthcare Solutions, INC. | $216.84 | 2019-2023 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $179.27 | 2019-2021 | |
| Genzyme Corporation | $155.34 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $131.82 | 2019-2021 | |
| Genentech USA, INC. | $126.58 | 2019-2023 | Xolair |
| Mylan Specialty L.P. | $113.32 | 2019-2022 | |
| Insmed, INC. | $110.44 | 2021-2023 | Arikayce |
| Astellas Pharma US INC | $49.09 | 2021 | |
| Pfizer INC. | $46.97 | 2019-2020 | |
| United Therapeutics Corporation | $46.49 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $39.89 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $20.00 | 2023 | Kcentra |
| Novartis Pharmaceuticals Corporation | $18.41 | 2019 | |
| Mallinckrodt Enterprises LLC | $18.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hellreich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.